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Background: Cutaneous squamous cell carcinoma (SCC) is the second most frequency of all skin tumors. Incidence
of SCC has risen significantly due to an increased sun exposure and the number of immunodeficient patients.
Cutaneous SCC is characterized by high Epidermal growth factor receptor (EGFR) expression with low frequency of
RAS mutations. Generally, locoregional surgery is curative and systemic therapy is not indicated. We evaluated the
activity and toxicity profile of tomotherapy concomitant with Cetuximab, followed by Cetuximab as single agent
therapy in a patient affected by unresectable, locally advanced cutaneous SCC.
Case presentation: At our institution, on March 2012 we treated a 45 years-old patient affected by locally
advanced, unresectable G1 SCC of the lumbar region. At our first observation, the patient was asthenic, with severe
pain and functional limitations. There was also a superinfection due to Pseudomonas Aeruginosa resistant to
antibiotics, and a G3 anemia secondary to the bleeding lesion. ECOG Performance Status was 2. Tomotherapy has
been performed concomitant with the Cetuximab (400 mg/m2, followed by weekly doses of 250 mg/m2) at the
total dose of 60 Gy (2 Gy/fx), followed by Cetuximab monotherapy.
The lesion reduced progressively until disappear even after the suspension of the treatment and the patient achieved
complete response. Toxicity resulted in G1 cutaneous rash and G2 toxicity to the nails, appeared after 5 months of
treatment, typical toxicity profile of the anti-EGFR therapies. After one month of therapy the Pseudomonas Aeruginosa
superinfection totally disappeared. Quality of life resulted significantly improved with reduction until discontinuation
of the anti-pain drugs, and progressive increase of the hemoglobin levels. At follow up of 15 months there was no
evidence of active disease and the ECOG Performance Status was 0 (zero).
Conclusion: The treatment was effective and feasible. Considering these excellent results, further studies about
concomitant tomotherapy with Cetuximab for advanced/inoperable SCC of the skin are needed.
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Cutaneous basal cell (BCC) and squamous cell carcinoma
(SCC), are the most common cancer in United States [1].
SCC is the second most frequent skin tumor [2]. More
than 3.000.000 new cases of SCC are diagnosed worldwide
every year [3]. Incidence of SCC has risen significantly due
to increased sun exposure and number of immunodefi-
cient patients [1,4,5]. If not radically excised, SCC become
invasive with tissue destruction and involvement of lymph
nodes, soft tissues, cartilages, and bones. Metastatic diffu-
sion is a rare phenomenon [1]. Generally, locoregional sur-
gery is curative and systemic therapy is not necessary [1].
Mohs micrographic surgery is an option to be taken in ac-
count. Radiation therapy (RT) is a therapeutic option in
advanced, unresectable SCC [1,6-8]. For advanced disease
chemotherapy has often palliative indication [9]. Cur-
rently, the great evolution of technology has allowed RT
to increase the compliance of the treatment administra-
tion and, at the same time, the reduction of the dose to
the surrounding normal tissue allowing an increase of the
dose to the tumor. Helical Tomotherapy (HT) delivery
represents a very important step in radiotherapic technical
innovation allowing improvement of dose conformation,
uniformity and normal tissues sparing. Cutaneous SCC is
characterized by high Epidermal growth factor receptor
(EGFR) expression with low frequency of RAS mutations.
These acquisitions support the potential efficacy of EGFR-
target therapies. Several published data demonstrate that
Cetuximab is an emerging alternative treatment for unre-
sectable cutaneous SCC [6,10-14].
The treatment of the tumor and the maximal preserva-
tion of function are important aim in the management of
cutaneous SCC. Development of Skin Cancer Index (SCI)
showed that healing, cosmetic and self-image, emotional
states such as anxiety and frustration were concerns
greater than physical handicaps [4,15].
We evaluated the activity and toxicity profile of a new
RT technology, HT, concomitant with Cetuximab, followed
by Cetuximab as single agent therapy in a patient af-
fected by unresectable, locally advanced SCC of the
skin. There are limited published data available for con-
comitant treatment of Cetuximab and HT in advanced
cutaneous SCC.
Case presentation
On March 2012 we visited a 45-year-old Caucasian
woman with a very extensive, untreated G1 cutaneous
SCC infiltrating widely the lumbar region until bone. A
physical examination showed a locally advanced lesions
with necrotic and ulcerated areas involving the entire
lumbar area until sacrum and buttocks. There was also a
superinfection due to Pseudomonas Aeruginosa resistant
to antibiotics. The patient referred functional limitation
in movement, difficulty in walking, pain, and consequentserious relationship problems with a worse status of
quality of life. The patient had G3 anemia due to the
bleeding lesion, and performed red blood cells transfu-
sion before to start the treatment. ECOG Performance
Status was 2. A contrast-enhanced magnetic resonance
(RM) of pelvis showed extensive skin thickening from
the front region of the iliac spine up to posterior sacral
region, involving the contralateral lumbar region. The le-
sion extended from the right of right iliac crest (where it
is in contact with the lateral abdominal muscles and
with the cortex of the iliac crest) until ipsilateral gluteal
region, involving deep muscular tissue.
The patient’s case was discussed by a multidisciplinary
committee involving surgeons, radiotherapists and on-
cologists. The patient was treated with Cetuximab at the
loading dose of 400 mg/m2, followed by weekly doses of
250 mg/m2,from 28 March 2012 to 13 March 2013. HT
has been performed concomitant with the Cetuximab
from 28 march 2012 to 19 May 2012, at the total dose of
60 Gy (2 Gy/fx).
Patient was immobilized in the prone position without
application of bolus. Planning computed tomography
(CT) images were acquired through the region of inter-
est using a 3 mm slice thickness and transferred to the
contouring workstation for TomoTherapy Hi · Art Sys-
tem®. Set up was based on fiducial markers and tattoo
aligned with a room laser system before treatment.
The gross target volume (GTV) was considered as
right gluteal region outlined based on the depth of in-
volvement and the extent of disease. Clinical target vol-
ume (CTV) was created adding a margin of 3 mm at
GTV. Doses to organs at risk (rectum, bladder, right and
left femur, right and left kidney, pubis, bowel) were de-
fined in accordance with dose constraints. Each therapy
session was preceded by a MVCT in order to ensure the
correct repositioning of the patient and to adjust the
distribution of the irradiation dose according with the
evolution of the tumor during therapy. The accepted tol-
erance at our institution was 5 mm. After a new CT scan
for contouring, a new treatment plan was elaborated at
30 Gy according with volumetric reduction of lesion.
The time of delivery (around 10 minutes for fractions)
were well tolerated by the patients. At the end of the
combined radio target therapy, Cetuximab treatment
continued for the following 10 months.
The patient achieved complete response, confirmed
at imaging evaluation, and the lesion reduced until
disappear even after the suspension of the treatment
(Figures 1 and 2). Toxicity resulted in G1 cutaneous rash
and G2 toxicity to the nails according to typical toxicity
profile of the anti-EGFR therapies, appeared 5 months
after treatment. One month after therapy the Pseudo-
monas Aeruginosa superinfection totally disappeared as
the G3 anemia.
Figure 1 On left the lesion at baseline (March 2012) and on right the lesion at follow up (October 2013).
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with progressive reduction until discontinuation of anti-pain
drugs. At follow up of 15 months there was no evidence of
active disease, moreover she was able to get back a normal
social life. Actually the ECOG Performance Status is 0 (zero).Figure 2 TC imaging: A baseline TC (December 2011); B simulation TC (MDiscussion
Surgery is the standard treatment of localized cutaneous
SCC [1]. Although Mohs surgery remains the standard
treatment for locally advanced SCC there is no safe and
effective non-surgical treatment for unresectable SCCarch 2012); C follow up (June 2013); D last follow up (February 2014).
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studies and there are few data from prospective trials.
According with NCCN guidelines, radiotherapy in the
management of skin cancers have indication 2A [1].
Two meta-analyses reported 10% of 5-year recurrence
rates after RT for the treatment of SCC [16,17]. RT is
considered the primary treatment of choice when surgi-
cal excision may result infunctional or with aesthetic
compromission or for extensive unresectable tumors
[1,18-20]. RT achieves excellent cosmetic results. It can
be delivered using orthovoltage radiation (for superficial
lesions), megavoltage electron beam technology (for dee-
per tissue) or brachytherapy (delivering radiation directly
at the lesion) [18]. IMRT is a special technique that war-
ranted to ensure adequate surface dose to the target area
sparing normal tissue [1]. HT is an innovative treatment
unit dedicated to IMRT and IGRT that consent a com-
bination between an helical CT scanner and a conven-
tional linear accelerator (LINAC). The RT is delivered in
helical modality. In fact the 6 MV LINAC is assembled
in a circular gantry similar to a CT scanner and rotates
in synchrony with couch movement creating a helical
trajectory. HT consent to acquire MVCT scans before to
deliver RT [21]. Due to this delivery system of “record
and verify”, HT allows to generate very complex dose
distributions with high doses to the entire tumor vol-
ume, sparing normal healthy tissue at the same time. For
advanced disease chemotherapy has often only a pallia-
tive indication. Sadek et al. [9] demonstrated that neoad-
juvant chemotherapy with cisplatin, 5-fluorouracil and
bleomycin followed by surgery can be curative (30% of
complete remission and 54% of partial remission). The
advent of systemic therapy targeted against the signaling
pathway provided a new important option for patients
with advanced disease unfit for local therapy [1]. EGFR
plays a crucial role in signal-transduction pathways
that regulate key cellular functions. Cetuximab is a
recombinant monoclonal antibody that competitively in-
hibits EGFR. Cetuximab specifically binds to the extra-
cellular domain of EGFR inducing an internalization of
the ligand–receptor complex and subsequent down-
regulation of intracellular signals [22,23]. Maubec et al.
evaluated in a phase II trial the effects of Cetuximab as
first line single agent in chemotherapy-naive unresectable
SCC. In this phse II trial cetuximab achieved 69% DCR
and 28% RR [13]. Recently, Preneau et al. [14] confirm the
potential interest of cetuximab to treat unresectable ad-
vanced SCC alone or combined with carboplatin based
chemotherapy or with radiotherapy.
Preclinical data on human tumor xenografts in nude
mice indicated that Cetuximab in combination with
radiotherapy improves local tumor control [24-26]. The
radiosensitizing effect of cetuximab is probably due to
regulation of cell cycle progression [27], blockage ofradiation-induced EGFR transport into the nucleus, and
interference with DNA repair mechanisms [28,29].
Moreover in head and neck squamous carcinomas, the
combination of radiotherapy plus cetuximab is widely
used in unresectable tumors.
Several studies evaluated the quality of life (QOL) per-
ceived by the patient before and after surgical treatment
[4]. Various indicators such as Skin Cancer Index (SCI)
evaluating domains of emotion, social factors, and ap-
pearance [30] and the Dermatology Life Quality Index
(DLQI) [31] or Skindex, reporting subscores on symp-
toms, emotional effects, and effects on functioning have
been used [32]. In our case the combined radio-target
treatment allowed the patient to achieve a significant
improvement in QoL for the disappearance of the symp-
toms, but also and especially for the opportunity to have
a social life again.
Conclusion
Only patients with locally advanced uresectable cutane-
ous SCC should be considered for radiation therapy with
or without target therapy. Advanced radiation therapy
techniques offer greater dose escalation to tumor vol-
umes while decreasing patient long term toxicity. HT is
an effective option as radical treatment or in association
with chemotherapy. Early and late toxicity and cosmetic
results are acceptable. The patient will continue to be
assessed in order to observe any recurrences. Consider-
ing these excellent results, further studies about con-
comitant Tomotherapy with Cetuximab for advanced/
inoperable SCC of the skin are needed.
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